RSRuth Simmons

Ruth Simmons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruth Simmons has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estimating the Fraction of Hepatocellular Carcinoma and Decompensated Cirrhosis Attributable to Viral Hepatitis in England Using Electronic Health Records and Case‐Notes Review

    by David Etoori, Annabel Powell, Paul Trembling, Jennifer Plunkett, Ashley Brown, Maud Lemoine, Stephen Ryder, Sarah Montague, Eleanor Pilsworth, Anthony Bains, et al.

    Viral hepatitis mortality is an impact target required to evidence the elimination of viral hepatitis with a combined mortality rate of less than or equal to six deaths per 100,000 population. Within England, routine healthcare data linked with death registrations are used; however, where these data are not available, the World Health Organization (WHO) recommends overlaying the attributable fraction (AF) over the mortality envelope for decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC). We aimed to estimate viral hepatitis mortality using the attributable fraction and compared it to surveillance methods. Six acute NHS trusts participated across England and reviewed the case records of individuals identified retrospectively up to 31 December 2023 through hospital episode statistics to confirm the diagnosis and complete a proforma on possible exposures and likely cause of DC/HCC. Overall, 563 individuals were identified, 390 for DC review with 127 (32.6%) confirmed and 173 for HCC review with 157 (91.8%) confirmed. The AF for DC was 0.008 for HCV and 0.016 for HBV, equivalent to a crude mortality rate of 0.09 per 100,000 population and 0.17 per 100,000 population, respectively. For HCC 0.1806 for HCV and 0.0645 for HBV, equivalent to 0.85 per 100,000 population and 0.30 per 100,000 population respectively. These results are comparable to applying the attributable fraction methodology to linking healthcare data sets and demonstrate that England continues to meet the WHO impact target.

  • Open Access

    Characterising Hepatitis D Virus in the UK From 2011 to 2021

    by R. Simmons, S. Ijaz, R. Jackson, K. Jack, R. Mulongeni, R. Raghu, A. Riddell, A. Elsharkawy, A. Uriel, A. Koffas, et al.

    Little is known about hepatitis B virus (HBV) and Hepatitis D virus (HDV) coinfection in the UK. HDV screening is recommended among all individuals with HBV, with coinfection associated with increased disease progression. Using data on HDV testing, shared by 11 laboratories in the UK who reported undertaking HDV testing, and national testing data for HBV we established a cohort of individuals tested for HDV, investigating testing pathways, describing characteristics and outcomes of those HDV‐RNA positive to inform targeted interventions for testing, diagnosis and linkage to care. Demographic information, clinical assessments, treatment and recent laboratory results from NHS trusts, and through linkage to national healthcare datasets was collected for HDV‐RNA positive individuals. Between 2011 and 2021, 42% of individuals newly diagnosed with HBV in England were linked to an HDV test. Anti‐HDV positivity was 5.0%, 55.8% were HDV‐RNA tested and 45.7% were ever HDV‐RNA positive. HDV‐RNA positivity in the absence of an anti‐HDV result was 6.4%. Among individuals who were HDV‐RNA positive, 94.3% were non‐UK born, with 24 different primary languages reported, 49% had evidence of treatment, and 48% had evidence of cirrhosis. 10% had died of which 58.4% died of liver disease. In conclusion, our findings indicate that HDV testing in HBV positive individuals in the UK is sub‐optimal against testing guidelines, including RNA testing among those who are anti‐HDV positive. Considerable work is needed to improve the patient care pathway, to ensure patients are appropriately diagnosed, linked and retained in care, with adequate access to treatment.

  • Open Access

    The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling

    by Zoe Ward, Ruth Simmons, Hannah Fraser, Adam Trickey, Joanna Kesten, Andrew Gibson, Leila Reid, Sean Cox, Fiona Gordon, Stuart McPherson, et al.

    Background: People who inject drugs are disproportionately affected by hepatitis C virus. The emergence of direct-acting antiviral treatments for hepatitis C virus motivated England to achieve the World Health Organization’s elimination target of decreasing hepatitis C virus incidence among people who inject drugs to < 2 per 100 person-years (/100 person-years) by 2030. We determined whether existing testing and treatment strategies will reach this target in England, or whether improved strategies are needed and whether they are cost-effective. Methods: A dynamic hepatitis C virus transmission model among people who inject drugs was developed for four English regions. The model included the pathway from testing to treatment in prisons, drug treatment centres and other settings. Each pathway was parameterised using region-specific data, with yearly bio-behavioural surveys among people who inject drugs being used to parameterise and calibrate the model in a Bayesian framework. The model projected whether each region will reach the hepatitis C virus incidence target or what improvements (in testing and linkage to treatment) are needed from 2024 to achieve it. Hepatitis C virus care pathway costs were collated through interviews with practitioners and the published literature. The mean incremental cost-effectiveness ratio (per quality-adjusted life-year saved) was estimated for any ‘improved’ strategy that reached the incidence target compared to the baseline strategy. Incremental cost-effectiveness ratios were compared to a willingness-to-pay threshold of £20,000/quality-adjusted life-year saved over a 50-year time horizon (3.5% annual discount rate). Results: Across the four regions over 2016–22, an estimated 8831–9689 treatments occurred among 37,230 people who inject drugs, with the annual number treated increasing in prisons (7.8 times) and drug treatment centres (3.6 times). Model projections suggest that hepatitis C virus incidence among people who inject drugs has decreased across the regions by 56.1–85.4% (range of medians) over 2015–22, with incidence decreasing by 79.7–98.6% to 0.2–2.2/100 person-years by 2030. The World Health Organization incidence target (< 2/100 person-years) will be reached with > 80% probability in three regions and 40% probability in the other region. The probability of reaching the incidence target increases to > 65% in this region if screening is increased in drug treatment centres (80% screened annually) or prisons (75% of people get tested during their prison stay), with these screening strategies being cost-effective. Conclusion: Numerous England regions may be on target to decrease hepatitis C virus incidence among people who inject drugs to < 2/100 person-years. In regions that are not on target, further scale-up of testing in drug treatment centre or prison from 2024 could enable them to reach the World Health Organization elimination target and be cost-effective. Limitations: Projections were based on model estimations, which need to be confirmed with empirical data. Data uncertainties affected our model projections, including uncertainty in the number of people who inject drugs in each region and the number of treatments given to people who inject drugs in different settings. Sample sizes for the yearly bio-behavioural surveys among people who inject drugs were small, and so samples were pooled over multiple years. Testing rates among people who inject drugs could not be directly estimated because the sentinel surveillance had incomplete coverage and could not identify people who inject drugs; testing rates were estimated through model calibration. Future work: There is interest in understanding what scale-back in testing can occur after 2030 without resulting in a rebound in hepatitis C virus incidence, and in developing models for each devolved nation to determine their progress to World Health Organization hepatitis C virus elimination targets. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR128513.

  • Open Access

    Barriers and facilitators along the Hepatitis C reinfection journey: Qualitative interview study

    by Avelie Stuart, Cristina Santamaria-Plaza, Matthew Hibbert, Ruth Simmons, Leila Reid, Mark Roberts, Jackie Moore, Monica Desai

    Among people who have experienced hepatitis C virus (HCV) reinfection, we examined the barriers and facilitators to preventing (re)infection with HCV, to seeking testing and treatment, and for prospective prevention of further reinfection. Remote semi-structured interviews (January-August 2024) were conducted with participants recruited via the Hepatitis C Trust and the National Health Service in England. The data were thematically analysed using the COM-B model, exploring how capability, opportunity, and motivation affect behaviour during participants’ journeys with (re)infection-testing-treatment. Six participants were interviewed including 1 female, 1 person who acquired HCV via sex, 1 person who received care in prison, and 5 people who injected drugs. Some people who inject drugs reported not feeling capable of preventing reinfections whilst injecting drugs. Additional capability barriers were lack of knowledge of transmission risks beyond needles/syringes, and knowledge of treatment. During subsequent treatment, participants reported better knowledge of transmission risks and treatment, and that peer support helped motivate them to complete treatment. Participants also reported less stigma from healthcare professionals since their initial infection or treatment. Their future reinfection prevention strategies included opportunity and motivational changes including changing their social circles and environment, prioritising their health, and engaging in volunteering. Therefore, health services are an opportunity for education and behaviour change interventions, including peer support programmes, to support prevention of reinfection. However gaps remain in continuity of care and harm reduction access, which are also needed to enable opportunities to prevent first time infections.

  • Open Access

    Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England

    by Laura T. Phillips, Daniel Bradshaw, Simon Packer, Ruth Simmons, William M. Rosenberg, Caroline A. Sabin, Jean L. Mbisa


  • Open Access

    Health and Experiences During the COVID-19 Pandemic Among Children and Young People: Analysis of Free-Text Responses From the Children and Young People With Long COVID Study

    by Natalia K Rojas, Sam Martin, Mario Cortina-Borja, Roz Shafran, Lana Fox-Smith, Terence Stephenson, Brian C F Ching, Anaïs D'OElsnitz, Tom Norris, Yue Xu, et al.

    Background: The literature is equivocal as to whether the predicted negative mental health impact of the COVID-19 pandemic came to fruition. Some quantitative studies report increased emotional problems and depression; others report improved mental health and well-being. Qualitative explorations reveal heterogeneity, with themes ranging from feelings of loss to growth and development. Objective: This study aims to analyze free-text responses from children and young people participating in the Children and Young People With Long COVID study to get a clearer understanding of how young people were feeling during the pandemic. Methods: A total of 8224 free-text responses from children and young people were analyzed using InfraNodus, an artificial intelligence–powered text network analysis tool, to determine the most prevalent topics. A random subsample of 411 (5%) of the 8224 responses underwent a manual sentiment analysis; this was reweighted to represent the general population of children and young people in England. Results: Experiences fell into 6 main overlapping topical clusters: school, examination stress, mental health, emotional impact of the pandemic, social and family support, and physical health (including COVID-19 symptoms). Sentiment analysis showed that statements were largely negative (314/411, 76.4%), with a small proportion being positive (57/411, 13.9%). Those reporting negative sentiment were mostly female (227/314, 72.3%), while those reporting positive sentiment were mostly older (170/314, 54.1%). There were significant observed associations between sentiment and COVID-19 status as well as sex (P=.001 and P<.001, respectively) such that the majority of the responses, regardless of COVID-19 status or sex, were negative; for example, 84.1% (227/270) of the responses from female individuals and 61.7% (87/141) of those from male individuals were negative. There were no observed associations between sentiment and all other examined demographics. The results were broadly similar when reweighted to the general population of children and young people in England: 78.52% (negative), 13.23% (positive), and 8.24% (neutral). Conclusions: We used InfraNodus to analyze free-text responses from a large sample of children and young people. The majority of responses (314/411, 76.4%) were negative, and many of the children and young people reported experiencing distress across a range of domains related to school, social situations, and mental health. Our findings add to the literature, highlighting the importance of specific considerations for children and young people when responding to national emergencies.


  • Open Access

    Estimating Prevalence and Number of People With Chronic Hepatitis B: A Multiplier Method Based on Public Health Surveillance Data in UK (2015–2021)

    by Ruth Simmons, Ross Harris, Aaron G. Lim, David Leeman, Mary E. Ramsay, Matthew Hickman, Sema Mandal

    Estimates of chronic hepatitis B virus (HBV) prevalence and critically the amount of infection that is undiagnosed or unlinked to care are uncertain—even in countries like UK where vertical transmission and overall prevalence are very low. In the absence of country of birth data, we aim to estimate HBV prevalence through combining public health surveillance data on antenatally screened women by ethnic group and multipliers generated from non‐antenatally screened populations by ethnic group with English population denominators. Of 714,287 women aged 16–49 years with ethnic group data tested as part of antenatal care between 2015 and 2021, 4174 (0.6%) were HBsAg‐positive; 94% in people of ethnic groups other than White British. Of 1,447,467 people tested for HBsAg with ethnic group data from other testing sources (primary and secondary care excluding occupational health and renal services), 27,628 (1.9%) were HBsAg‐positive; 87% in people of ethnic groups other than White British. We estimate that the overall number and prevalence of people with chronic hepatitis B in England is 268,767 (95% CI: 227,896–314,044) and 0.58% (95% CI: 0.50–0.68). Approximately two‐thirds were male, one‐third female, and 68% were aged under 50. We estimate that over 83% of HBV infections are in people of ethnic groups other than White British, with 23% in people from Black ethnic groups, 21% from other White ethnic groups and 19% in Asian ethnic groups. These estimates are the first step towards establishing whether England can meet World Health Organisation targets to eliminate HBV as a public health problem—using methods that can also be used by other countries.


  • Open Access

    Health and Experiences During the COVID-19 Pandemic Among Children and Young People: Analysis of Free-Text Responses From the Children and Young People With Long COVID Study (Preprint)

    by Natalia K Rojas, Sam Martin, Mario Cortina-Borja, Roz Shafran, Lana Fox-Smith, Terence Stephenson, Brian C F Ching, Anaïs D'Oelsnitz, Tom Norris, Yue Xu, et al.

    BACKGROUND The literature is equivocal as to whether the predicted negative mental health impact of the COVID-19 pandemic came to fruition. Some quantitative studies report increased emotional problems and depression; others report improved mental health and well-being. Qualitative explorations reveal heterogeneity, with themes ranging from feelings of loss to growth and development. OBJECTIVE This study aims to analyze free-text responses from children and young people participating in the Children and Young People With Long COVID study to get a clearer understanding of how young people were feeling during the pandemic. METHODS A total of 8224 free-text responses from children and young people were analyzed using InfraNodus, an artificial intelligence–powered text network analysis tool, to determine the most prevalent topics. A random subsample of 411 (5%) of the 8224 responses underwent a manual sentiment analysis; this was reweighted to represent the general population of children and young people in England. RESULTS Experiences fell into 6 main overlapping topical clusters: school, examination stress, mental health, emotional impact of the pandemic, social and family support, and physical health (including COVID-19 symptoms). Sentiment analysis showed that statements were largely negative (314/411, 76.4%), with a small proportion being positive (57/411, 13.9%). Those reporting negative sentiment were mostly female (227/314, 72.3%), while those reporting positive sentiment were mostly older (170/314, 54.1%). There were significant observed associations between sentiment and COVID-19 status as well as sex (P=.001 and P<.001, respectively) such that the majority of the responses, regardless of COVID-19 status or sex, were negative; for example, 84.1% (227/270) of the responses from female individuals and 61.7% (87/141) of those from male individuals were negative. There were no observed associations between sentiment and all other examined demographics. The results were broadly similar when reweighted to the general population of children and young people in England: 78.52% (negative), 13.23% (positive), and 8.24% (neutral). CONCLUSIONS We used InfraNodus to analyze free-text responses from a large sample of children and young people. The majority of responses (314/411, 76.4%) were negative, and many of the children and young people reported experiencing distress across a range of domains related to school, social situations, and mental health. Our findings add to the literature, highlighting the importance of specific considerations for children and young people when responding to national emergencies.

  • Open Access

    Developing survey weights to ensure representativeness in a national, matched cohort study: results from the children and young people with Long Covid (CLoCk) study

    by Natalia K Rojas, Bianca L De Stavola, Tom Norris, Mario Cortina-Borja, Manjula D Nugawela, Dougal Hargreaves, Emma Dalrymple, Kelsey McOwat, Ruth Simmons, Terence Stephenson, et al.

    Background: Findings from studies assessing Long Covid in children and young people (CYP) need to be assessed in light of their methodological limitations. For example, if non-response and/or attrition over time systematically differ by sub-groups of CYP, findings could be biased and any generalisation limited. The present study aimed to (i) construct survey weights for the Children and young people with Long Covid (CLoCk) study, and (ii) apply them to published CLoCk findings showing the prevalence of shortness of breath and tiredness increased over time from baseline to 12-months post-baseline in both SARS-CoV-2 Positive and Negative CYP. Methods: Logistic regression models were fitted to compute the probability of (i) Responding given envisioned to take part, (ii) Responding timely given responded, and (iii) (Re)infection given timely response. Response, timely response and (re)infection weights were generated as the reciprocal of the corresponding probability, with an overall ‘envisioned population’ survey weight derived as the product of these weights. Survey weights were trimmed, and an interactive tool developed to re-calibrate target population survey weights to the general population using data from the 2021 UK Census. Results: Flexible survey weights for the CLoCk study were successfully developed. In the illustrative example, re-weighted results (when accounting for selection in response, attrition, and (re)infection) were consistent with published findings. Conclusions: Flexible survey weights to address potential bias and selection issues were created for and used in the CLoCk study. Previously reported prospective findings from CLoCk are generalisable to the wider population of CYP in England. This study highlights the importance of considering selection into a sample and attrition over time when considering generalisability of findings.


  • Open Access

    Factors associated with human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual and other men who have sex with men in the UK – findings from the large community-based RiiSH-Mpox survey

    by George Baldry, Dawn Phillips, Ruth Wilkie, Marta Checchi, Kate Folkard, Ruth Simmons, John Saunders, Sema Mandal, Catherine H Mercer, Hamish Mohammed, et al.

    Background Gay, bisexual, and other men who have sex with men (GBMSM) face a disproportionate burden of sexually transmitted infections and are eligible for targeted vaccinations for hepatitis A (HAV), hepatitis B (HBV), human papilloma virus (HPV) and mpox. This study examines the sociodemographic characteristics, sexual behaviours, and sexual healthcare service (SHS) use associated with vaccination uptake. Methods We undertook analyses of RiiSH-Mpox - an online, community-based survey with GBMSM recruited via social media and dating apps. We calculated vaccination uptake (≥1 dose) among eligible GBMSM. Bivariate and multivariable logistic regression was performed to identify factors independently associated with vaccination uptake among eligible participants. Results Reported uptake in eligible GBMSM was around two-thirds for each of the vaccinations considered: mpox 69% (95% confidence interval (CI): 66%-72%), HAV 68% (CI:65%-70%), HBV 72% (CI:69%-74%) and HPV 65% (CI:61%-68%). Vaccination course completion (receiving all recommended doses) ranged from 75% (HBV) to 89% (HAV) among eligible GBMSM. Individuals who represented missed opportunities for vaccination ranged from 22-30% of eligible SHS attendees. Younger participants, individuals identifying as bisexual, reporting lower educational qualifications, or being unemployed reported lower uptake across GBMSM-selective vaccinations. Individuals who reported greater levels of sexual behaviour and recent SHS use were more likely to report vaccinations. Conclusion Eligible participants reported high uptake of vaccinations; however, uptake was lower amongst young GBMSM and self-identifying bisexual men. Awareness of groups with lower vaccination uptake will help inform practice, delivery strategies and health promotion, to improve the reach and impact of vaccinations amongst GBMSM. Contributions DP, RW, KF, CHM, JS, HM reviewed and updated the survey instrument. Survey implementation, data collection and data management were carried out by RW and DO. GB, CM, DO, HM curated secondary analysis plan with review and contributions from KF, MC, JS, RS, SM. GB conducted analysis and completed the first manuscript draft. All authors contributed to successive drafts and reviewed and approved the final manuscript. Ethics statement Ethical approval of this study was provided by the UKHSA Research and Ethics Governance Group (REGG; ref: R&D 524). Online informed consent was received from all participants and all methods were performed in accordance with guidelines and regulations set by the UKHSA REGG. Competing interests Authors have no competing interests to declare. Data availability statement The data that support the findings of this study are available upon reasonable request from the UK Health Security Agency (UKHSA). Requests can be directed to Dr Hamish Mohammed ( hamish.mohammed{at}ukhsa.gov.uk ). Funding This study did not receive any funding and was conducted as part of the UKHSA public health response to mpox.